مجله علوم پزشکی صدرا

هورمون درمانی سرطان سینه با بیان رسپتور هورمونی، مروری بر تاثیر بر بقای بیماران و چالش‌های پیش‌روی

نوع مقاله : مقاله مروری

نویسندگان

دنا فیروزآبادی 1
نوید اسمعیل زاده شهری 1
محمدامین جعفرزاده 1، 2
فاطمه سفلائی شهربابک 3
مریم شهریارفر 1

1 گروه داروسازی بالینی، دانشکده داروسازی شیراز، دانشگاه علوم پزشکی شیراز، شیراز، ایران

2 کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی شیراز، شیراز، ایران

3 دانشکدهٔ داروسازی و علوم دارویی، دانشگاه آزاد اسلامی، واحد علوم پزشکی تهران، تهران، ایران

https://doi.org/10.30476/smsj.2026.109136.1704
چکیده
این مقاله مروری روایتی بر اهمیت هورمون‌درمانی در بیماران مبتلا به سرطان پستان با بیان رسپتورهای هورمونی تمرکز دارد. اگرچه این زیرگروه از بیماری در مقایسه با سایر انواع سرطان پستان معمولاً پیش‌آگهی بهتری دارد، اما نیاز به درمان هورمونی طولانی‌مدت همچنان چالش‌های متعددی را در عمل بالینی روزمره ایجاد می‌کند. بر اساس شواهد منتشرشده، داروهایی مانند تاموکسیفن، لتروزول، آناستروزول، اگزمستان و فولوسترانت می‌توانند خطر عود بیماری را کاهش داده و میزان مرگ‌ومیر را کم می‌کنند که در نهایت منجر به بهبود بقای بیماران می‌شود. در عین حال، بیماران اغلب با عوارض ناخواسته متعددی از جمله علائم یائسگی، دردهای اسکلتی‌عضلانی، کاهش تراکم استخوان، افت عملکرد شناختی و مشکلات مرتبط با سلامت جنسی مواجه می‌شوند. این عوارض جانبی ارتباط مستقیمی با کاهش پایبندی بیماران به درمان دارند. در این مقاله، تأثیر داروهای هورمونی بر بقا همراه با مهم‌ترین چالش‌های مرتبط با عوارض درمان مرور شده است. همچنین برخی روش‌های حمایتی و رویکردهای درمانی جدید به‌عنوان راهکارهای احتمالی برای کنترل این مشکلات مورد بررسی قرار گرفته‌اند. در مجموع، هورمون‌درمانی همچنان باید به‌عنوان بخش اساسی درمان سرطان پستان با رسپتور هورمونی مثبت در نظر گرفته شود، اما اثربخشی این روش تا حد زیادی به آگاهی بیماران از ضرورت ادامه درمان و راهکارهای کاهش عوارض جانبی آن وابسته است.

تازه های تحقیق

Dena Firouzabadi (Google Scholar)
Navid Esmaeilzadeh Shahri (Google Scholar)

کلیدواژه‌ها

نئوپلاسم‌های پستان
هورمون
دستگاه غدد درون‌ریز
میزان بقا
عوارض و واکنش‌های نامطلوب ناشی از داروها
عوارض جانبی
پایبندی به درمان دارویی
  1. Curtin SC, Tejada-Vera B, Bastian BA. Deaths: leading causes for 2020. Natl Vital Stat Rep. 2023;72(4):1-106.
  2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
  3. Sedeta ET, Jobre B, Avezbakiyev B. Breast cancer: global patterns of incidence, mortality, and trends. Alexandria: American Society of Clinical Oncology; 2023.
  4. Obeagu EI, Obeagu GU. Breast cancer: a review of risk factors and diagnosis. Medicine (Baltimore). 2024;103(3):e36905.
  5. Smolarz B, Nowak AZ, Romanowicz H. Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel). 2022;14(10):2569.
  6. Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med (Lausanne). 2017;4:227.
  7. Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor–positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34(25):3069-103.
  8. Awan A, Esfahani K. Endocrine therapy for breast cancer in the primary care setting. Curr Oncol. 2018;25(4):285-92.
  9. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ. Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol. 2014;382(1):695-723.
  10. Sainsbury R. The development of endocrine therapy for women with breast cancer. Cancer Treat Rev. 2013;39(5):507-17.
  11. Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med Chem. 2015;7(12):1511-9.
  12. Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021;11(8):808.
  13. Karn V, Sandhya S, Hsu W, Parashar D, Singh HN, Jha NK, et al. CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope. Cancer Cell Int. 2022;22(1):234.
  14. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535.
  15. Lau KH, Tan AM, Shi Y. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci. 2022;23(4):2288.
  16. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37(4):496-513.
  17. Haggstrom LR, Vardy JL, Carson EK, Segara D, Lim E, Kiely BE. Effects of endocrine therapy on cognitive function in patients with breast cancer: a comprehensive review. Cancers (Basel). 2022;14(4):920.
  18. Condorelli R, Vaz-Luis I. Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther. 2018;18(11):1101-12.
  19. AlOmeir O, Patel N, Donyai P. Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory. Support Care Cancer. 2020;28(11):5075-84.
  20. Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: updated review. Ochsner J. 2017;17(4):405-11.
  21. Krauss K, Stickeler E. Endocrine therapy in early breast cancer. Breast Care (Basel). 2020;15(4):337-46.
  22. Benkhadra K, Mohammed K, Al Nofal A, Carranza Leon BG, Alahdab F, Faubion S, et al. Menopausal hormone therapy and mortality: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(11):4021-8.
  23. Smith I, Yardley D, Burris HA, De Boer R, Amadori D, McIntyre K, et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor–positive, node-positive early breast cancer: final results of the randomized phase III Femara versus Anastrozole clinical evaluation (FACE) trial. J Clin Oncol. 2017;35(10):1041-8.
  24. Sendur M, Aksoy S, Zengin N, Altundag K. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer. J BUON. 2013;18(4):838-44.
  25. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122-37.
  26. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107-18.
  27. Abo-Touk NA, Sakr HA, Abd El-Lattef A. Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer. J Egypt Natl Canc Inst. 2010;22(1):79-85.
  28. Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221-31.
  29. Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016;387(10021):849-56.
  30. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-41.
  31. Nabholtz J, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 2000;18(22):3758-67.
  32. Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, et al. Long-term follow-up of the intergroup exemestane study. J Clin Oncol. 2017;35(22):2507-14.
  33. Derks MG, Blok EJ, Seynaeve C, Nortier JW, Kranenbarg EM, Liefers GJ, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(9):1211-20.
  34. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. J Clin Oncol. 2013;31(11):1398-404.
  35. Kittaneh M, Glück S. Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl). 2011;5:BCBCR-S6234.
  36. Walker G, Xenophontos M, Chen L, Cheung K. Long-term efficacy and safety of exemestane in the treatment of breast cancer. Patient Prefer Adherence. 2013;7:245-58.
  37. Buzdar AU, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006;40(9):1572-83.
  38. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22(9):1605-13.
  39. Pfeiler G, Konigsberg R, Singer C, Seifert M, Dubsky P, Samonigg H, et al. Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: an analysis of the ABCSG-12 trial. J Clin Oncol. 2010;28(15 Suppl):512.
  40. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29(19):2653-9.
  41. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411-5.
  42. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. 2019;380(13):1226-34.
  43. Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019;37(2):105-14.
  44. Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. J Clin Oncol. 2015;33(25):2772-9.
  45. Mamounas EP, Bandos H, Rastogi P, Lembersky BC, Jeong JH, Geyer CE Jr, et al. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst. 2023;115(11):1302-9.
  46. Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst. 2018;110(1):40-8.
  47. Van Asten K, Neven P, Lintermans A, Wildiers H, Paridaens R. Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocr Relat Cancer. 2014;21(1):R31-49.
  48. Osborne C, Wakeling A, Nicholson R. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2-6.
  49. Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2010;73(3):220-7.
  50. Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;33(32):3781-7.
  51. Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997-3005.
  52. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage. 2002;23(6):501-9.
  53. Rosenberg SM, Partridge AH. Premature menopause in young breast cancer: effects on quality of life and treatment interventions. J Thorac Dis. 2013;5(Suppl 1):S55-61.
  54. Pinkerton J, Santen R. Managing vasomotor symptoms in women after cancer. Climacteric. 2019;22(6):544-52.
  55. Cole KM, Clemons M, Alzahrani M, Liu M, Larocque G, MacDonald F, et al. Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience. Support Care Cancer. 2022;30(5):4437-46.
  56. Sahni S, Lobo-Romero A, Smith T. Contemporary non-hormonal therapies for the management of vasomotor symptoms associated with menopause: a literature review. Touch Rev Endocrinol. 2021;17(2):133-40.
  57. Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015;152(2):231-7.
  58. Carpenter JS, Storniolo AM, Johns S, Monahan PO, Azzouz F, Elam JL, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist. 2007;12(1):124-35.
  59. Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303-13.
  60. Biglia N, Bounous VE, De Seta F, Lello S, Nappi RE, Paoletti AM. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. Ecancermedicalscience. 2019;13:909.
  61. Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50.
  62. Bounous VE, Andronico N, Govone F, Giorgi M, Actis S, D’Alonzo M, et al. New challenges in treatments for menopausal symptoms in breast cancer survivors. Maturitas. 2020;139:1-7.
  63. Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;222(6):564.e1-79.e12.
  64. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057-71.
  65. Carpenter J, Gass ML, Maki PM, Newton KM, Pinkerton JV, Taylor M, et al. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155-74.
  66. Conklin M, Santoro N. Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause. Ther Adv Reprod Health. 2023;17:26334941231177611.
  67. Walsh JS. Normal bone physiology, remodelling and its hormonal regulation. Surgery (Oxford). 2018;36(1):1-6.
  68. Zhu Y, Koleck TA, Bender CM, Conley YP. Genetic underpinnings of musculoskeletal pain during treatment with aromatase inhibitors for breast cancer: a biological pathway analysis. Biol Res Nurs. 2020;22(2):263-76.
  69. Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase inhibitor-associated musculoskeletal syndrome: understanding mechanisms and management. Front Endocrinol (Lausanne). 2021;12:632595.
  70. Kyvernitakis I, Kostev K, Hadji P. The tamoxifen paradox—influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. Osteoporos Int. 2018;29(11):2557-64.
  71. Stumpf U, Kostev K, Kyvernitakis I, Böcker W, Hadji P. Incidence of fractures in young women with breast cancer—a retrospective cohort study. J Bone Oncol. 2019;18:100254.
  72. De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):474-85.
  73. Journé F, Body JJ, Leclercq G, Laurent G. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health. Expert Opin Drug Saf. 2008;7(3):241-58.
  74. Yardley DA. Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press). 2016;8:73-82.
  75. Park JB. The effects of fulvestrant, an estrogen receptor antagonist, on the proliferation, differentiation and mineralization of osteoprecursor cells. Mol Med Rep. 2013;7(2):555-8.
  76. Xu X, Li X, Liang Y, Ou Y, Huang J, Xiong J, et al. Estrogen modulates cartilage and subchondral bone remodeling in an ovariectomized rat model of postmenopausal osteoarthritis. Med Sci Monit. 2019;25:3146-53.
  77. Lintermans A, Neven P. Safety of aromatase inhibitor therapy in breast cancer. Expert Opin Drug Saf. 2015;14(8):1201-11.
  78. Robarge JD, Duarte DB, Shariati B, Wang R, Flockhart DA, Vasko MR. Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons. Exp Neurol. 2016;281:53-65.
  79. Beckwée D, Leysen L, Meuwis K, Adriaenssens N. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer. 2017;25(5):1673-86.
  80. Rosso R, D’Alonzo M, Bounous VE, Actis S, Cipullo I, Salerno E, et al. Adherence to adjuvant endocrine therapy in breast cancer patients. Curr Oncol. 2023;30(2):1461-72.
  81. Al-Mubarak M, Sacher AG, Ocana A, Vera-Badillo F, Seruga B, Amir E. Fulvestrant for advanced breast cancer: a meta-analysis. Cancer Treat Rev. 2013;39(7):753-8.
  82. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9(9):866-72.
  83. Vergote I, Robertson JF. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br J Cancer. 2004;90(Suppl 1):S11-4.
  84. Stepan JJ, Hruskova H, Kverka M. Update on menopausal hormone therapy for fracture prevention. Curr Osteoporos Rep. 2019;17(6):465-73.
  85. Miyashita H, Satoi S, Kuno T, Cruz C, Malamud S, Kim SM. Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Res Treat. 2020;181(2):279-89.
  86. Fessele KL, editor. Bone health considerations in breast cancer. Semin Oncol Nurs. 2022;38(3):151301.
  87. Bauer M, Bryce J, Hadji P. Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Med Press). 2012;4:91-101.
  88. Paschou SA, Augoulea A, Lambrinoudaki I. Bone health care in women with breast cancer. Hormones (Athens). 2020;19(2):171-8.
  89. Ramchand SK, Cheung YM, Yeo B, Grossmann M. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241(3):R111-24.
  90. Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017;7:1-12.
  91. Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916-46.
  92. Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol. 2020;31(12):1650-63.
  93. Shapiro CL. Bone-modifying agents (BMAs) in breast cancer. Clin Breast Cancer. 2021;21(5):e618-30.
  94. Subramanian CR, Talluri S, Mullangi S, Lekkala MR, Moftakhar B. Review of bone modifying agents in metastatic breast cancer. Cureus. 2021;13(2):e13407.
  95. Byun JH, Jang S, Lee S, Park S, Yoon HK, Yoon BH, et al. The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis. J Bone Metab. 2017;24(1):37-49.
  96. Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339-51.
  97. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291-6.
  98. Grossmann M, Ramchand SK, Milat F, Vincent A, Lim E, Kotowicz MA, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary. Med J Aust. 2019;211(5):224-9.
  99. Bae K, Lamoury G, Carroll S, Morgia M, Lim S, Baron-Hay S, et al. Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a systematic review with network meta-analysis. Crit Rev Oncol Hematol. 2023;181:103898.
  100. Donnellan P, Douglas S, Cameron D, Leonard R. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001;19(10):2767.
  101. Menas P, Merkel D, Hui W, Lawton J, Harper A, Carro G. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. J Oncol Pharm Pract. 2012;18(4):387-93.
  102. Rocque G. What is the role of symptom management and patient-reported outcomes in adherence to aromatase inhibitors? J Clin Oncol. 2018;36(4):308-9.
  103. Kanematsu M, Morimoto M, Honda J, Nagao T, Nakagawa M, Takahashi M, et al. The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer. 2011;11:436.
  104. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115(16):3631-9.
  105. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83.
  106. Gupta A, Henry NL, Loprinzi CL. Management of aromatase inhibitor–induced musculoskeletal symptoms. JCO Oncol Pract. 2020;16(11):733-9.
  107. Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA. 2018;320(2):167-76.
  108. Chen L, Lin CC, Huang TW, Kuan YC, Huang YH, Chen HC, et al. Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: a meta-analysis of randomized controlled trials. Breast. 2017;33:132-8.
  109. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007;129(1-2):210-23.
  110. Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, et al. Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Res Treat. 2018;172(3):603-10.
  111. Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, et al. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol. 2018;36(4):326-32.
  112. Schnell PM, Lustberg MB, Henry NL. Adverse events and perception of benefit from duloxetine for treating aromatase inhibitor-associated arthralgias. JNCI Cancer Spectr. 2021;5(2):pkab029.
  113. Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(1):127-38.
  114. Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, et al. Correction: quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. Br J Cancer. 2020;122(7):1119.
  115. Cantarero-Villanueva I, Fernández-Lao C, Caro-Morán E, Morillas-Ruiz J, Galiano-Castillo N, Díaz-Rodríguez L, et al. Aquatic exercise in a chest-high pool for hormone therapy-induced arthralgia in breast cancer survivors: a pragmatic controlled trial. Clin Rehabil. 2013;27(2):123-32.
  116. Barbosa KdP, da Silva LGT, Garcia PA, Freitas CdA, da Silva ECF, Pereira TV, et al. Effectiveness of pilates and circuit-based exercise in reducing arthralgia in women during hormone therapy for breast cancer: a randomized, controlled trial. Support Care Cancer. 2021;29(10):6051-9.
  117. Oh B, Kimble B, Costa D, Davis E, McLean A, Orme K, et al. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study. Acupunct Med. 2013;31(3):264-71.
  118. Ram-Weiner M, Paluch-Shimon S, Allweis TM, Lev-Sagie A. Vaginal health in breast cancer survivors: a practical clinical approach. Ther Adv Med Oncol. 2025;17:17588359251344007.
  119. Boswell EN, Dizon DS. Breast cancer and sexual function. Transl Androl Urol. 2015;4(2):160-7.
  120. da Silva Filho PPP, Capassi ACS, Haddad CF, Santos LA, Maia MV, Hatamoto NY, et al. Sexual quality of life in hormonotherapy for breast cancer patients. Braz J Oncol. 2022;18:e2022001.
  121. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611-35.
  122. Sussman TA, Kruse ML, Thacker HL, Abraham J. Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy. J Oncol Pract. 2019;15(7):363-70.
  123. McVicker L, Labeit AM, Coupland CA, Hicks B, Hughes C, McMenamin Ú, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103-8.
  124. Juraskova I, Jarvis S, Mok K, Peate M, Meiser B, Cheah BC, et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (olive oil, vaginal exercise, and moisturizer) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med. 2013;10(10):2549-58.
  125. Taranto P, de Brito Sales D, Maluf FC, Guendelmann RAK, de Melo Pompei L, Leal A, et al. Safety and efficacy of topical testosterone in breast cancer patients receiving ovarian suppression and aromatase inhibitor therapy. Breast Cancer Res. 2024;26(1):133.
  126. Barton DL, Pugh SL, Ganz PA, Plaxe SC, Koontz BF, Carter J, et al. Randomized controlled phase II evaluation of two dose levels of bupropion versus placebo for sexual desire in female cancer survivors: NRG-CC004. J Clin Oncol. 2022;40(4):324-34.
  127. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf. 2010;2:141-50.
  128. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-8.
  129. Hungr C, Sanchez-Varela V, Bober SL. Self-image and sexuality issues among young women with breast cancer: practical recommendations. Rev Invest Clin. 2017;69(2):114-22.
  130. Myers JS, Cook-Wiens G, Baynes R, Jo MY, Bailey C, Krigel S, et al. Emerging from the haze: a multicenter, controlled pilot study of a multidimensional, psychoeducation-based cognitive rehabilitation intervention for breast cancer survivors delivered with telehealth conferencing. Arch Phys Med Rehabil. 2020;101(6):948-59.
  131. Falk SJ, Bober S. Vaginal health during breast cancer treatment. Curr Oncol Rep. 2016;18(5):32.
  132. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313-9.
  133. Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause. 2004;11(5):519-30.
  134. Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Pers Med. 2015;5(2):50-66.
  135. Biglia N, Bounous VE, D’Alonzo M, Ottino L, Tuninetti V, Robba E, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;17(8):611-7.
  136. Schover LR, Baum GP, Fuson LA, Brewster A, Melhem-Bertrandt A. Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors. J Sex Med. 2014;11(12):3102-11.
  137. Bellet M, Gray KP, Francis PA, Láng I, Ciruelos E, Lluch A, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol. 2016;34(14):1584-93.
  138. ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93-6.
  139. Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: an update. World J Clin Oncol. 2022;13(2):71-100.
  140. Lambertini M, Arecco L, Woodard TL, Messelt A, Rojas KE. Advances in the management of menopausal symptoms, fertility preservation, and bone health for women with breast cancer on endocrine therapy. Am Soc Clin Oncol Educ Book. 2023;43:e390442.
  141. Aihara T, Yokota I, Hozumi Y, Aogi K, Iwata H, Tamura M, et al. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. Breast Cancer Res Treat. 2014;148(2):337-43.
  142. Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016;387(10021):866-73.
  143. Boccardo F, Guglielmini P, Bordonaro R, Fini A, Massidda B, Porpiglia M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial. Eur J Cancer. 2013;49(7):1546-54.
مجله علوم پزشکی صدرا
دوره 14، شماره 2
تابستان 1405
صفحه 518-540

صفحه اصلی

راهنمای نویسندگان

ارسال مقاله

راهنمای داوران

تماس با ما